Riskpilot← Back to searchSign inGet full accessWalmed AB
ABActiveOrg 5567192819Älgskyttevägen 19Business and other management consultancy activities · NACE 7020Est. 20071-4 employees
Revenue 2025
SEK 1,6M
0% vs 2024
EBITDA margin
35.2%
-20% vs 2024
Equity ratio
59.5%
Financial strength
Net profit 2025
SEK 331K
-19% vs 2024
| Revenue | SEK 1,6M | +0% |
| EBITDA | SEK 578K | -20% |
| Net profit | SEK 331K | -19% |
| Total assets | SEK 1,6M | +14% |
| Equity | SEK 938K | +55% |
| Employees | — | — |
Legal name
Walmed AB
Org number
5567192819
Legal form
Aktiebolag
NACE code
7020 · Business and other management consultancy activities
Founded
3 januari 2007
Share capital
SEK 100 000
Employees
1-4
VAT registered
Yes
Audit selected
No
Last report
2025-06-30
Financial year
January – December
Signatory rights
Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Bolaget ska bedriva konsultverksamhet såsom verksamhetsutveckling, affärsutveckling, marknadsstrategier och management, utveckling, distribution och försäljning av produkter inom Life Science-området samt därmed förenlig verksamhet. Bolaget skall även bedriva fotografverksamhet, så som eventfoto, produktfoto, bröllopsfoto och därmed förenlig verksamhet.
Address
Älgskyttevägen 19
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 380 | 1 649 | 1 645 |
| Staff expenses | — | — | −145 | −656 | −765 |
| EBITDA | −1 | −1 | 152 | 727 | 578 |
| Depreciation & amort. | −0 | −0 | −1 | −2 | −2 |
| EBIT | −1 | −1 | 151 | 725 | 577 |
| Net financials | — | — | — | 0 | 23 |
| Profit before tax | −1 | −1 | 112 | 530 | 434 |
| Tax | −0 | −0 | −24 | −121 | −103 |
| Net profit | −1 | −1 | 88 | 409 | 331 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 147 | 146 | 471 | 1 388 | 1 577 |
| Equity | 111 | 110 | 198 | 607 | 938 |
| Long-term debt | 0 | 0 | — | — | — |
| Short-term debt | 36 | 36 | 235 | 548 | 239 |
| Total debt | 36 | 36 | 235 | 548 | 239 |
EBITDA margin
35.2%
This company
15.8%
Market median
+123% vs market
20212025
Equity ratio
59.5%
This company
38.2%
Market median
+56% vs market
20212025
Return on equity
35.3%
This company
18.4%
Market median
+92% vs market
20212025
Net profit margin
20.1%
This company
8.1%
Market median
+148% vs market
20212025
Asset turnover
1.04×
This company
1.12×
Market median
+7% vs market
20212025
Debt / equity
0.68×
This company
0.62×
Market median
+10% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-07-01 – 2025-06-30
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-07-01 – 2024-06-30
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-07-01 – 2023-06-30
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-07-01 – 2022-06-30
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-07-01 – 2021-06-30
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
KK Chief Executive Officer | Chief Executive Officer | 2024 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Walmed AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Karl Kristian Waldeck | Chief Executive Officer | 0 companies |
| Eva Maria Cecilia Waldeck | Deputy Board Member | 0 companies |